ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) and Pulse Biosciences (NASDAQ:PLSE – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for ENDRA Life Sciences and Pulse Biosciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ENDRA Life Sciences | 1 | 0 | 1 | 0 | 2.00 |
| Pulse Biosciences | 1 | 0 | 1 | 0 | 2.00 |
ENDRA Life Sciences currently has a consensus price target of $50.00, suggesting a potential upside of 1,062.79%. Pulse Biosciences has a consensus price target of $22.00, suggesting a potential upside of 69.10%. Given ENDRA Life Sciences’ higher probable upside, equities analysts plainly believe ENDRA Life Sciences is more favorable than Pulse Biosciences.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ENDRA Life Sciences | N/A | N/A | -$11.51 million | ($26.45) | -0.16 |
| Pulse Biosciences | $700,000.00 | 1,259.55 | -$53.58 million | ($1.13) | -11.51 |
ENDRA Life Sciences has higher earnings, but lower revenue than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares ENDRA Life Sciences and Pulse Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ENDRA Life Sciences | N/A | -396.15% | -190.40% |
| Pulse Biosciences | N/A | -67.70% | -58.89% |
Volatility & Risk
ENDRA Life Sciences has a beta of -0.09, meaning that its share price is 109% less volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500.
Insider and Institutional Ownership
1.2% of ENDRA Life Sciences shares are owned by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are owned by institutional investors. 10.0% of ENDRA Life Sciences shares are owned by company insiders. Comparatively, 74.6% of Pulse Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Pulse Biosciences beats ENDRA Life Sciences on 7 of the 10 factors compared between the two stocks.
About ENDRA Life Sciences
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
About Pulse Biosciences
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
